Literature DB >> 2833999

Medial thalamic injection of opioid agonists: mu-agonist increases while kappa-agonist decreases stimulus thresholds for pain and reward.

K D Carr1, T H Bak.   

Abstract

Selective agonists for mu- and kappa-opioid receptor types were infused, bilaterally, into the intralaminar central lateral nucleus of the rat. Subcataleptic doses of the mu-agonist, DAGO (0.25 and 1.0 microgram), elevated tailshock threshold for eliciting pain vocalization and motor responses. The hyperalgesic effect of U50,488 is not likely to be the result of antagonist action at a mu 2-isoreceptor; the general mu-antagonist, naloxone, and its less lipophilic quaternary analogue, both failed to produce a significant reduction in pain thresholds. Paralleling their effects on pain, DAGO and U50,488 elevated and reduced, respectively, lateral hypothalamic electrical stimulation threshold for positive reinforcement. These results suggest that medial thalamic opioid mechanisms are not exclusively involved in pain modulation but may generally regulate the responsiveness of the organism to motivating stimuli. Moreover, mu- and kappa-receptors may mediate opposite behavioral effects of opioid peptides.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833999     DOI: 10.1016/0006-8993(88)91396-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Alterations in endogenous opioid functional measures in chronic back pain.

Authors:  Ilkka K Martikainen; Marta Peciña; Tiffany M Love; Emily B Nuechterlein; Chelsea M Cummiford; Carmen R Green; Richard E Harris; Christian S Stohler; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

2.  mu-Opioid peptides inhibit thalamic neurons.

Authors:  J Brunton; S Charpak
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

3.  Effects of early-life FGF2 on ultrasonic vocalizations (USVs) and the mu-opioid receptor in male Sprague-Dawley rats selectively-bred for differences in their response to novelty.

Authors:  Cortney A Turner; Megan H Hagenauer; Elyse L Aurbach; Pamela M Maras; Chelsea L Fournier; Peter Blandino; Rikav B Chauhan; Jaak Panksepp; Stanley J Watson; Huda Akil
Journal:  Brain Res       Date:  2019-03-14       Impact factor: 3.252

4.  Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus.

Authors:  Michelle R Hoot; Laura J Sim-Selley; Dana E Selley; Krista L Scoggins; William L Dewey
Journal:  Brain Res       Date:  2011-06-16       Impact factor: 3.252

5.  Central beta-endorphin system involvement in the reaction to acute tonic pain.

Authors:  C A Porro; G Tassinari; F Facchinetti; A E Panerai; G Carli
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

6.  It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder.

Authors:  D T Hsu; B J Sanford; K K Meyers; T M Love; K E Hazlett; S J Walker; B J Mickey; R A Koeppe; S A Langenecker; J-K Zubieta
Journal:  Mol Psychiatry       Date:  2015-01-20       Impact factor: 15.992

7.  mu-opioid receptor-mediated antinociceptive responses differ in men and women.

Authors:  Jon-Kar Zubieta; Yolanda R Smith; Joshua A Bueller; Yanjun Xu; Michael R Kilbourn; Douglas M Jewett; Charles R Meyer; Robert A Koeppe; Christian S Stohler
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

8.  An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus.

Authors:  Chunqiao Liu; Yanshu Wang; Philip M Smallwood; Jeremy Nathans
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

9.  Response of the μ-opioid system to social rejection and acceptance.

Authors:  D T Hsu; B J Sanford; K K Meyers; T M Love; K E Hazlett; H Wang; L Ni; S J Walker; B J Mickey; S T Korycinski; R A Koeppe; J K Crocker; S A Langenecker; J-K Zubieta
Journal:  Mol Psychiatry       Date:  2013-08-20       Impact factor: 15.992

10.  Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine.

Authors:  Courtney M Cameron; Steven Nieto; Lucienne Bosler; Megan Wong; Isabel Bishop; Larissa Mooney; Catherine M Cahill
Journal:  Adv Drug Alcohol Res       Date:  2021-08-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.